PLZF and its fusion proteins are pomalidomide-dependent CRBN neosubstrates
Shimizu et al. identify PLZF/ZBTB16 and its fusion proteins as pomalidomide-dependent neosubstrates of the cereblon E3 ligase. The authors also report that pomalidomide induces their degradation and thereby exerts its anti-cancer effect in leukemic cells expressing the fusion proteins.
Enregistré dans:
Auteurs principaux: | Nobuyuki Shimizu, Tomoko Asatsuma-Okumura, Junichi Yamamoto, Yuki Yamaguchi, Hiroshi Handa, Takumi Ito |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/8e042573d7f949a6bd3a74bcd451d1ff |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Targeting the acute promyelocytic leukemia-associated fusion proteins PML/RARα and PLZF/RARα with interfering peptides.
par: Sabine Beez, et autres
Publié: (2012) -
Characterisation of genome-wide PLZF/RARA target genes.
par: Salvatore Spicuglia, et autres
Publié: (2011) -
Crbn modulates calcium influx by regulating Orai1 during efferocytosis
par: Hyunji Moon, et autres
Publié: (2020) -
Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma
par: Mary H. Young, et autres
Publié: (2021) -
pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase
par: Jian An, et autres
Publié: (2017)